In this issue

Highlighted research articles

Important news stories affecting the community

Shelved 4-1BB Antibodies
Make Comeback

Selected highlights of recent articles of exceptional significance from the cancer literature

For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.

Views

In the Spotlight

Drug-Resistant Brain Metastases: A Role for Pharmacology, Tumor Evolution, and Too-Late Therapy

The SIN1-PH Domain Connects mTORC2 to PI3K

Large-Scale Drug Screens Support Precision Medicine

In Focus

All the World’s a Stage: Facilitating Discovery Science and Improved Cancer Care through the Global Alliance for Genomics and Health

Research Briefs

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

P.A. Konstantinopoulos, R. Ceccaldi, G.I. Shapiro, and A.D. D’Andrea

EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib


Précis: Clinically observed in-frame tandem duplication of the EGFR kinase domain is a recurrent oncogenic driver alteration in NSCLC and confers sensitivity to EGFR inhibitors.

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets


Précis: Sequencing of matched primary tumors and brain metastases reveals branched evolution and frequent oncogenic alterations in potentially targetable pathways.

See commentary, p. 1124
RESEARCH ARTICLES

NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition


Précis: Loss of NF2 promotes thyroid tumorigenesis by increasing expression of both wild-type and mutant RAS in a YAP-dependent manner, resulting in enhanced dependency on MAPK signaling.

See commentary, p. 1127

Harnesing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset


Précis: Integration of small-molecule cancer cell line sensitivity profiles with known drug targets and genomic features reveals context-driven vulnerabilities and small-molecule mechanisms of action.

See commentary, p. 1130

AC icon indicates Author Choice
For more information please visit http://www.aacrjournals.org

ON THE COVER

Garcia-Rendueles, Ricarte-Filho, and colleagues found that chr22q LOH is a common event in poorly differentiated thyroid cancer (PDTC) and is preferentially associated with RAS mutations. In mice, neither thyroid-specific activation of Hras nor NF2 deletion was sufficient for transformation, but their combined disruption led to highly penetrant PDTC characterized by increased MAPK signaling. Inactivation of the Hippo pathway in NF2-deficient cells increased YAP-mediated transcription of wild-type and mutant RAS isoforms, whereas disruption of YAP–TEAD binding blocked RAS transcription and inhibited cancer cell growth. Additionally, NF2 loss sensitized RAS-mutant thyroid cancer cells to MEK inhibitors. These results identify YAP as a critical effector of RAS-induced tumorigenesis and suggest that inhibition of YAP or MEK may be effective in RAS-driven thyroid cancer. For details, please see the article by Garcia-Rendueles, Ricarte-Filho, and colleagues on page 1178.